Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 2/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435111 | 0.94 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1CNR2 | |
| SCHEMBL13435118 | 0.83 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1MEN1MAPT | |
| SCHEMBL13500286 | 0.83 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1KLK7CNR2 | |
| SCHEMBL13499749 | 0.83 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1KLK7METAP2 | |
| SCHEMBL13461547 | 0.80 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1KLK7METAP2 | |
| SCHEMBL13435113 | 0.79 | CPB2 (0.40) | SLC1A3SLC1A2SLC1A1MEN1MAPT | |
| SCHEMBL13435112 | 0.78 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1MEN1MAPT | |
| SCHEMBL13435117 | 0.78 | CPB2 (0.40) | SLC1A3SLC1A2SLC1A1MEN1MAPT | |
| SCHEMBL13435104 | 0.78 | CPB2 (0.40) | SLC1A3SLC1A2SLC1A1MEN1MAPT | |
| SCHEMBL13435114 | 0.78 | CPB2 (0.40) | SLC1A3SLC1A2SLC1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-7498324-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | SLC1A3 1088/4885SLC1A2 706/4885SLC1A1 1042/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.